DDR1 antibodies are designed to inhibit or modulate DDR1, a transmembrane receptor that binds collagen and regulates extracellular matrix (ECM) remodeling. DDR1 is overexpressed in epithelial cancers (e.g., breast, lung, pancreatic) and fibrotic diseases, where it promotes tumor invasion, metastasis, and immune evasion .
Target: Extracellular domain (ECD) or kinase domain of DDR1 .
Applications: Research (e.g., immunohistochemistry, Western blot), therapeutic development .
Relevance: High DDR1 expression correlates with poor prognosis in cancers and resistance to immunotherapy .
DDR1 antibodies disrupt collagen-DDR1 interactions or downstream signaling:
Immune Exclusion: DDR1 promotes collagen fiber alignment, forming a physical barrier that excludes CD8+ T cells from tumors. Antibodies like PRTH-101 disrupt this barrier, restoring antitumor immunity .
Metastasis: DDR1 activation in pancreatic cancer induces CXCL5 secretion, recruiting neutrophils and driving metastasis via NETosis .
Therapeutic Synergy: Combining DDR1 antibodies (e.g., PRTH-101) with PD-1 inhibitors enhances tumor regression in microsatellite-stable colorectal cancer models .
Immune Modulation: DDR1 antibodies reverse immune exclusion, sensitizing tumors to checkpoint inhibitors .
Biomarker-Driven Use: High DDR1/collagen I expression predicts response in colorectal, breast, and lung cancers .
Safety: PRTH-101 shows no significant toxicity in Phase 1 trials, supporting further development .
Target Specificity: DDR1 and DDR2 share structural homology, necessitating selective antibodies .
Resistance Mechanisms: Tumor heterogeneity and compensatory pathways (e.g., alternative collagen receptors) may limit efficacy.
Combination Strategies: Ongoing trials explore DDR1 antibodies with chemotherapy, radiation, or immunotherapy .